EssermanLJ; WISDOM Study and Athena Investigators. The WISDOM Study: Breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer, 2017; 3:34.
2.
PatelNS, LeeM, MartiJL. Assessment of screening mammography recommendations by Breast Cancer Centers in the U.S. JAMA Intern Med, 2021; 181:717–719.
3.
HabibAR, GradyD, RedbergRF. Recommendations from breast cancer centers for frequent screening mammography in younger women may do more harm than good. JAMA Intern Med, 2021; 181:588–589.
4.
EssermanLJ, ShiehY, RutgersEJ, et al.Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat, 2011; 130:725–734.
5.
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA, 2002; 288:321–333.
6.
RavdinPM, CroninKA, HowladerN, et al.The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med, 2007; 356:1670–1674.
7.
EssermanLJ, YauC, ThompsonCK, et al.Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. Jama Oncol, 2017; 3:1503.
8.
AnderssonC, JohnsonAD, BenjaminEJ, LevyD, VasanRS. 70-Year legacy of the Framingham Heart Study. Nat Rev Cardiol, 2019; 16:687–698.
9.
ShiehY, EklundM, MadlenskyL, et al.Breast cancer screening in the precision medicine era: Risk-based screening in a population-based trial. J Natl Cancer Inst, 2017; 109:djw290.
10.
BurnsideES, Trentham-DietzA, ShaferCM, et al.Age-based versus risk-based mammography screening in women 40–49 years old: A cross-sectional study. Radiology, 2019; 292:321–328.
